Of everything this site catalogues, nothing produces sharper disbelief than a single comparison: a class of therapy that lists at US$373,000–525,000 per infusion in the United States lists at ¥999,000–1.29 million (roughly US$140,000–180,000) in China — a peer-reviewed figure, not a vlog. That is a third of the price for the same category of treatment, and the gap is widening in China’s favour. Here is what is actually documented behind that number, and what it does and does not mean for a patient. Nothing here is treatment advice.
The pipeline came first
CAR-T — a patient’s own T cells engineered to attack their cancer, then re-infused — entered China in 2021, when Fosun Kite’s relma-cel became the country’s first approved CAR-T. Since then the market has widened steadily: by mid-2026 Chinese media counted eight marketed CAR-T products, across more manufacturers than any other country. In June 2026 came the approval that made oncologists outside China take notice: CARsgen’s satri-cel for advanced gastric cancer, the world’s first regulatory approval of a CAR-T for a solid tumour — a class no Western regulator has yet cleared. A therapy space where China is not catching up but leading approvals is one where price comparisons stop being a curiosity.
Then the prices moved
US list prices have only ratcheted upward — Yescarta and Tecartus at $373,000, Kymriah at $475,000, Carvykti at $465,000, and the newest approval at $525,000. China’s have ratcheted downward: one manufacturer has signalled a launch price of ¥230,000–250,000 for its next product, attributing the drop to localised, non-customised production. Two directions of travel, one widening gap.
The more radical experiments are in how patients pay, not just how much. Fosun Kite’s nationwide outcomes-based plan refunds up to ¥600,000 — around half the list price — for patients who do not respond, a structure with little parallel in the US market. In 2025 a national commercial-insurance innovative-drug catalogue negotiated five CAR-T products in, with patient out-of-pocket expected around ¥40,000 per dose — while no CAR-T had entered the state reimbursement drug list as of September 2025 (peer-reviewed review). A $400,000 therapy reaching some Chinese patients at four figures of out-of-pocket is, on its face, the biggest cost story in the specialty anywhere.
Why the gap, honestly
Three documented drivers: manufacturing scale and domestic competition across eight products; payment innovation (outcomes refunds, insurance catalogue negotiations) that pushes risk onto manufacturers; and, less flatteringly, the fact that list-price comparisons flatter both sides. A 2026 cost analysis documents how total episode-of-care costs — lymphodepletion, hospitalisation, complication management — run well past the drug price itself, in both countries. And Chinese approvals cover indications defined by Chinese regulators, occasionally with no FDA-approved equivalent anywhere, which cuts both ways: earlier access, and fewer external checks on that access.
What it does not mean
For a foreign patient, none of this is a flight booking. CAR-T is prescribed for specific blood cancers under specific conditions; eligibility and follow-up belong with oncologists, and a cell-therapy episode does not fit inside a brief medical trip. Foreign self-pay patients negotiate with hospitals’ international departments at close to list prices — the insurance-catalogue prices are for domestic policies — and foreign insurers almost never fund planned treatment abroad. The full sourced landscape, including every figure above, is maintained on our advanced oncology and cell therapy page; the general cost comparisons live in the cost section.
The reason this story gets attention is not that China’s system is “better”. It is that one country found a route to a fraction of the price in the most expensive therapy class in medicine — and published the receipts.